ABCA3 Deficiency: an unusual cause of respiratory distress in the newborn by Anandarajan, Mugilan et al.
© The Ulster Medical Society, 2009. www.ums.ac.uk
Ulster Med J 2009; 78 (1) 51-52
Royal Jubilee Maternity Hospital, Belfast HSC Trust, Belfast, BT12 6BB, 
United Kingdom
Correspondence to Dr Tubman
richard.tubman@belfasttrust.hscni.net
Case Report
ABCA3 Deficiency: an unusual cause of respiratory distress in 
the newborn
Mugilan Anandarajan, Sunil Paulraj, Richard Tubman
Accepted 6 September 2008
ABSTRACT:
Respiratory Distress Syndrome (RDS) is due to deficiency 
of surfactant and commonly occurs in preterm babies. We 
report the first confirmed case in Northern Ireland of ABCA3 
transporter deficiency which is a rare but important cause of 
RDS in term babies.
A  38  week  gestation  female  infant  developed  respiratory 
distress  at  four  hours  of  age.  Chest  radiography  was 
consistent with RDS. The baby required repeated doses of 
surfactant, each resulting in transient periods of decreased 
ventilatory requirement and improvement in blood gases, but 
unfortunately she did not survive. 
DNA sequencing demonstrated two different mutations in the 
ABCA3 gene, one inherited from each parent. The baby was 
therefore a compound heterozygote, and both mutations were 
thought to be functionally significant.
ABCA3 transporter deficiency is a genetic disorder that is 
increasingly recognized as a cause of RDS in term babies in 
whom congenital deficiency of surfactant B and abnormalities 
of surfactant protein C have been excluded. It should be 
considered in mature babies who develop severe RDS.
INTRODUCTION:
Respiratory Distress Syndrome (RDS) is due to deficiency of 
surfactant and commonly occurs in preterm babies1. However, 
the condition can also occur in term babies and may be due 
to abnormalities of surfactant production. Surfactant protein 
B deficiency and abnormalities of protein C are recognized 
causes of abnormal surfactant2. Recent studies indicate that 
mutations in the ABCA3 transporter gene are a significant 
cause of RDS in term babies3.We report the first confirmed 
case of ABCA3 transporter deficiency in Northern Ireland.
CASE REPORT: 
A  baby  girl  was  born  at  38  weeks  gestation  to  non-
consanguineous  parents.  Her  mother  was  a  primigravida 
whose membranes had ruptured three weeks prior to delivery. 
She had been treated with antibiotics for five days but was 
systemically well. The baby required no active resuscitation 
at  birth  but  developed  severe  respiratory  distress  by  four 
hours of age.
Initial  investigations  showed  a  high  white  cell  count,  a 
normal  C-reactive  protein  and  a  white-out  of  both  lung 
fields on chest radiograph, consistent with RDS (Figure 1). 
Blood cultures, respiratory viral screen, immunology profile, 
karyotype, ultrasound of abdomen and echocardiograph were 
all normal. 
She was treated with antibiotics and required mechanical 
ventilation  and  surfactant  replacement.  Her  condition  did 
not improve as expected, and she subsequently required high 
frequency  oscillatory  ventilation  and  multiple  additional 
doses of surfactant. There were brief periods of decreased 
ventilatory requirements and improvement in blood gases 
following each dose of surfactant, but the effects wore off 18 
to 24 hours after each treatment.
A provisional diagnosis of congenital surfactant deficiency 
was made. Broncho-alveolar lavage (BAL) was performed 
to  test  for  surfactant  proteins  B  and  C,  and  blood  was 
obtained for DNA analysis. The baby’s condition continued 
Fig 1. Chest radiograph showing severe RDS© The Ulster Medical Society, 2009.
52 The Ulster Medical Journal
www.ums.ac.uk
to deteriorate and on day 25 of life, after discussions with 
parents and family, intensive care was withdrawn and she 
died peacefully.
Subsequently, surfactant protein B was detected in adequate 
concentrations in BAL fluid. DNA sequencing demonstrated a 
mutation in coding exon 8 on one allele of the baby’s ABCA3 
gene resulting in substitution of arginine for glycine (G378R, 
where G refers to Glycine and R refers to Arginine). There 
was a second mutation in the last base coding exon 18 that 
led to substitution of arginine for glycine in codon 1002 
(G1002R). Both were non-conservative substitutions. One of 
these mutations was detected in analysis of the mother’s DNA 
and the other mutation in the father’s. Hence the baby was a 
compound heterozygote, with critically significant effects on 
her lung function (Fig 2).
DISCUSSION: 
Surfactant is a complex substance containing phospholipids 
and four different types of surfactant proteins: hydrophilic 
proteins  SP-A  and  SP-D  and  the  hydrophobic  proteins 
SP-B and SP-C. Surfactant is produced in the endoplasmic 
reticulum  of  the  pulmonary  type  II  alveolar  cells.  It  is 
stored  in  the  lamellar  bodies  and  released  from  cells  by 
exocytosis. After exocytosis surfactant undergoes a series 
of morphological changes to form a multilayered lipid rich 
coating at the air/ liquid interface in the alveoli.
Surfactant lowers alveolar surface tension, thereby stabilizing 
the  lungs  at  the  end  of  expiration,  and  preventing  end-
expiratory collapse. It also protects lungs against epithelial 
injury and provides a barrier against infection. Deficiency 
is  common  in  preterm  babies  and  results  in  respiratory 
distress syndrome, which is effectively treated with surfactant 
replacement. Recently, deficiency of surfactant proteins B and 
C, and of ABCA3 have been shown to be causes of RDS in 
more mature, term babies.
ABCA3 is a 1704 amino acid protein of the ATP binding 
cassette transporter family, whose exact function is as yet 
unknown. It is widely expressed in type II epithelial cells 
of the lung and is detected in the limiting membranes of 
the lamellar bodies which suggests that it is involved in the 
inward transport of lipids for the production of surfactant. 
Mutations of the ABCA3 gene may lead to the transport of 
abnormal lipids into these bodies leading to the production of 
abnormal or absent surfactant4. Evidence is accumulating of a 
range of different mutations in the ABCA3 gene5.
The carrier rate of this condition is unknown but was thought 
to be extremely rare. ABCA3 transporter deficiency may be 
more common than originally believed6. The baby described 
here was unfortunate to have inherited two different mutations 
from her parents, leading to abnormal surfactant function and 
clinical features of severe RDS. Currently the only curative 
treatment  available  is  lung  transplantation  without  which 
most babies will not survive beyond 3 to 6 months of life. 
This treatment is however not readily available and highly 
problematic in very young infants. 
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Fig 2. DNA sequencing showing two ABCA 3 mutations (arrowed)